

## ***Cynata Therapeutics Receives Notice of Allowance from European Patent Office for Cymerus™ Patent Application***

**Melbourne, Australia; 7 May 2018:** Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that a Notice of Allowance has been received from the European Patent Office (EPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application entitled “Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

The Notice of Allowance is sent to the applicant when the EPO intends to issue a patent. The patent will expand the already strong IP protection of the Cymerus platform and its unique ability to manufacture mesenchymal stem cells (MSCs) at scale, from one donor, one time, to create therapeutic grade stem cell treatments.

“We have a very comprehensive patent portfolio to protect our unique and proprietary IP and will continue to strengthen it with further applications,” said Dr Ross Macdonald, Cynata’s Chief Executive Officer. “The ability of the platform to enable manufacture of consistent, high-quality mesenchymal stem cell therapeutic products at scale is key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide. Our phase I clinical trial in patients with steroid resistant graft-versus-host-disease (GvHD) is well underway and with further pre-clinical studies in progress there is significant opportunity to expand our IP.”

The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and shareholders of Cynata.

Cynata anticipates that the patent will be granted by 14 September 2018, with an expiration date of 16 March 2031.

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO, 0412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Daniel Paproth, Australia Media Contact, 0421 858 982 , [daniel.paproth@mcpartners.com.au](mailto:daniel.paproth@mcpartners.com.au)  
Laura Bagby, U.S. Media Contact, 312-448-8098, [lbagby@6degreespr.com](mailto:lbagby@6degreespr.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.